Direct Journal Access for Research Agents
Product manager at Cohere on enterprise AI search infrastructure and deep research agents
The real product gap is no longer better crawling, it is privileged access to the right corpus for each task. Open web search can find a paper, but it still forces the agent to sift through publisher pages, SEO layers, and mixed quality results. In medicine, finance, and law, the winning research products are increasingly the ones that plug directly into trusted, domain specific sources and make those sources traceable inside the workflow.
-
In the Cohere interview, the practical complaint is speed and fidelity. Parallel through Manus can already assemble strong reports, but it reaches medical studies by browsing the public web first. That adds extra hops and more noise than a direct journal level connector would.
-
Medicine already shows why this matters. OpenEvidence gained traction by grounding answers in medical papers and then deepened that edge through exclusive partnerships with NEJM and JAMA. The data source itself became part of the moat, not just the model or interface.
-
Finance shows the same pattern in another vertical. AlphaSense competes by bundling broker research, filings, earnings calls, expert transcripts, and internal company data in one searchable system. Customers evaluate it on source breadth, source validity, and audit trail, not just answer fluency.
This points toward research agents that route each query to a purpose built stack, medical journals for clinical questions, filings and broker notes for investing, case law and precedents for legal work. As the open web fills with recycled AI content, distribution rights, trusted integrations, and source level workflow design will matter more than generic search quality.